For extensive-stage SCLC (ES-SCLC), the standard first-line treatment typically comprises chemotherapy or immunotherapy combined with chemotherapy, yet there is a distinct lack of therapeutic research specifically addressing the subset of ES-SCLC patients harboring ROS1 fusions, which hampers the establishment of clinical evidence for effective treatment strategies. This evidence concerns the gene ROS1 and small cell lung carcinoma.